// April 18, 2024
USP’s commitment to ESG considerations for a healthier, more sustainable world
At the U.S.
At the U.S.
The development of generic versions of innovator medicines is a global public health need.
To help strengthen the pharmaceutical supply chain and guard against potential shortages that can
The quality of medicine and how it’s delivered to patients is fundamental to treating illness and